NCT04565561Unknown不适用
Neovas Versus DCB for Coronary de Novo Lesions in Patients With STEMI: a Prospective Observational Clinical Trial
Shenzhen People's Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- late lumen loss (LLL)
研究概览
简要总结
a prospective, single center, observational clinical trail. Aim to to compare the efficacy and safety of the Bioabsorbable scaffold (BRS) Neovas BRS and Drug-coating balloon (DCB) in the treatment of STEMI patients with coronary artery disease and to further evaluate the safety and effectiveness of the two new interventional methods in STEMI intervention, so as to better guide clinical practice.
详细描述
- To study the advantages and disadvantages of Neovas BRS and DCB in interventional treatment of de novo lesions in STEMI patients, in order to better guide the clinical.
- To explore the safety of Neovas BRS in interventional treatment of ide novo lesions in STEMI patients.
- To explore the safety of DCB in interventional treatment of de novo lesions in STEMI patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years old (2) STEMI patients suitable for PPCI operation. Chest pain for more than 20 minutes; At least 2 leads ST-T segment elevation > 1 mm, or new LBBB, or myocardial infarction confirmed by echocardiography; It is expected that the reperfusion treatment can be successfully implemented within 12 hours after the occurrence of acute myocardial infarction.
- •(3) Target vessels are suitable for PPCI and Single vessel disease (non culprit vessel stenosis < 50%). It is a primary coronary lesion; Reference vessel diameter > 2.5mm and < 4mm, lesion length < 20mm; There is no obvious calcification at the lesion site; After thrombus aspiration or pre dilation balloon pretreatment, the residual stenosis < 30% has no blood flow restrictive dissection.
- •(4) Patients refused to accept drug-eluting stent implantation, voluntarily participated and signed informed consent, accepted and was willing to cooperate with follow-up, and was willing to cooperate with standard secondary prevention and treatment of coronary heart disease.
排除标准
- •The age is less than 18 years old; Previous history of myocardial infarction or post coronary stent operation; Left main disease; It is known that it is contraindications or resistance to the following drugs: bevaludine, low molecular heparin, common heparin, aspirin, clopidogrel / tegrelol; Participate in other clinical studies and interfere with the study; It is uncertain whether there is any neurological injury: for example, after resuscitation; It needs tracheal intubation / artificial ventilation; There was cardiogenic shock before grouping; It is known that there are intracranial diseases: occupying position, aneurysm, arteriovenous malformation, hemorrhagic cerebrovascular accident, ischemic cerebrovascular accident; Internal bleeding such as gastrointestinal bleeding before selection; It is planned to perform major surgical treatment within 6 weeks; Serious infectious disease, malignant tumor disease, serious blood disease and autoimmune disease; in recent March, there has been a history of large-dose use of immunosuppressant; Non coronary vasculitis and thrombotic diseases (vasculitis, aortic dissection, abdominal aneurysm); Serious mental illness patients; The life expectancy is less than 1 year; No consent to participate in the study.
结局指标
主要结局
late lumen loss (LLL)
时间窗: 1-year
The primary endpoint in-segment is late lumen loss (LLL) with follow-up of 1 year.
次要结局
- target lesion revascularization (TLR)(1-year)
- cardiac death(1-year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
ovel DCB for Coronary Artery Disease TrialIshemic cardiac diseaseJPRN-UMIN000037805Boston Scientific Japan K.K.180
已完成
不适用
ovel DCB for Coronary Artery Disease TrialCoronary Artery DiseaseJPRN-UMIN000036420Zeon Medical Inc. Business Development Depertment220
已完成
不适用
Intravascular Ultrasound Versus Angiography Guided Drug-coated BalloonCoronary Artery DiseaseNCT04255043Nanjing First Hospital, Nanjing Medical University260
已完成
1 期
De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo LesionsCoronary Artery StenosisNCT00934752C. R. Bard24
终止
4 期
The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot StudyCoronary StenosisStable AnginaNCT01899235Aalborg University Hospital